In the recent years there have been tremendous advances in the medical management of gynaecologic cancers. We will discuss this current landscape in the medical management of cervical, ovarian and endometrial cancers. Cervical cancer Is currently the 4th most common cancer worldwide and the 4th most important cause of cancer related death in females. Though cervical cancer incidence and mortality are expected to decline due to HPV vaccination, it still remains a major public health problem especially in developing nations. In Cervical Cancer, in the definitive setting, systemic therapy is used in addition to locoregional treatments either surgery or radiotherapy and in the palliative setting in patients with recurrent disease or metastasis at the outset. The antiangiogenic anti -vascular endothelial growth factor antibody bevacizumab has been shown to improve outcomes in patients with metastatic or advanced disease. Immunotherapy is also emerging in providing durable responses in pre-treated patients with advanced disease. Ovarian cancer is the 20th most commonly diagnosed cancer worldwide but is the most lethal gynaecologic cancer. Most patients require chemotherapy upfront either in the neoadjuvant setting or in the adjuvant setting and also on recurrence. Standard chemotherapy is carboplatin and paclitaxel. Dose dense chemotherapy has been investigated. Targeted agents like bevacizumab have shown to improve outcomes and Poly (ADP-ribose) polymerase inhibitors are also promising. In Endometrial cancer, systemic therapy is used in recurrent, metastatic or high-risk disease. Carboplatin and paclitaxel are increasingly used and preferred. DNA mismatch repair (dMMR) or microsatellite instability (MSI) positive endometrial cancers, may benefit from pembrolizumab.